Open AccessCytokine-regulating activity of anti-virus preparation CelAgripus in Burkitt's lym-phoma stable B-cell lines
Author(s) -
Alexander N. Narovlyansky,
M. V. Mezentseva,
И. А. Суетина,
Л. И. Руссу,
А М Иванова,
В. В. Полосков,
A V Izmest'eva,
T P Ospelnikova,
A. A. Sarymsakov,
Ф. И. Ершов
Publication year - 2019
Publication title -
voprosy virusologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.151
H-Index - 15
eISSN - 2411-2097
pISSN - 0507-4088
DOI - 10.36233/0507-4088-2019-64-4-165-172
Subject(s) - cytokine , raji cell , burkitt's lymphoma , cell culture , microbiology and biotechnology , interferon , biology , epstein–barr virus , virus , interleukin 4 , chemistry , virology , lymphoma , immunology , genetics
Cytokines activated in response to immunosuppressive viral infections can directly or indirectly affect the neoplastic transformation of B cells. In this study, we studied a new substance designed to produce the antiviral drug CelAgrip (CA, CelAgripus), which exhibits interferon (IFN) and cytokine-inducing activity and, apparently, can be used as an activator of antiviral immunity. Purpose - is to evaluate the cytokine-regulating effect of CA in Burkitt's lymphoma (LB) cell lines latently infected with the Epstein-Barr virus (EBV).